Table 2. Results of US Laboratory Respondents by Type of Laboratory.
| Question | US laboratories, No. (%) |
Results by type of laboratory, No. (%) | |||
|---|---|---|---|---|---|
| Hospital/medical center (academic) | Hospital/medical center (nonacademic) |
Nonhospital laboratory | Physician office laboratory/clinic | ||
| 1. Is your laboratory aware of the 2021 CKD-EPI equations for eGFR that do not include race adjustment factors?a | |||||
| Yes | 2859 (76.9) | 603 (80.1) | 1503 (76.8) | 554 (76.9) | 199 (68.9) |
| No | 859 (23.1) | 150 (19.9) | 453 (23.2) | 166 (23.1) | 90 (31.1) |
| Total | 3718 | 753 | 1956 | 720 | 289 |
| 2. Has your laboratory adopted the 2021 CKD-EPI creatinine equation for eGFR reporting?b | |||||
| Yes | 1124 (30.3) | 241 (32.1) | 568 (29.1) | 248 (34.6) | 67 (23.2) |
| No | 2059 (55.5) | 415 (55.3) | 1116 (57.2) | 356 (49.7) | 172 (59.5) |
| Unsure | 525 (14.2) | 95 (12.6) | 268 (13.7) | 112 (15.6) | 50 (17.3) |
| Total | 3708 | 751 | 1952 | 716 | 289 |
| 3. When does your laboratory plan to adopt the 2021 CKD-EPI creatinine equation for eGFR reporting?c | |||||
| Before July 1, 2022 | 440 (21.6) | 96 (23.6) | 256 (23.2) | 53 (15.0) | 35 (20.7) |
| Between July 1 and December 31, 2022 | 218 (10.7) | 47 (11.5) | 125 (11.3) | 36 (10.2) | 10 (5.9) |
| 2023 or later | 45 (2.2) | 10 (2.5) | 23 (2.1) | 9 (2.5) | 3 (1.8) |
| Unsure | 1187 (58.4) | 227 (55.8) | 644 (58.3) | 219 (62.0) | 97 (57.4) |
| Not applicable; do not plan to implement this equation | 144 (7.1) | 27 (6.6) | 57 (5.2) | 36 (10.2) | 24 (14.2) |
| Total | 2034 | 407 | 1105 | 353 | 169 |
| 4. Does your laboratory plan to adopt the 2021 CKD-EPI creatinine–cystatin C equation for eGFR reporting?d | |||||
| Yes | 292 (8.0) | 67 (8.9) | 149 (7.7) | 56 (7.9) | 20 (7.0) |
| No | 1174 (32.0) | 237 (31.6) | 590 (30.5) | 240 (34.0) | 107 (37.5) |
| Unsure | 2082 (56.7) | 418 (55.8) | 1128 (58.4) | 383 (54.3) | 153 (53.7) |
| Not applicable; we have already implemented this equation | 123 (3.4) | 27 (3.6) | 65 (3.4) | 26 (3.7) | 5 (1.8) |
| Total | 3671 | 749 | 1932 | 705 | 285 |
| 5. Are there any barriers impacting your laboratory’s consideration or adoption of the 2021 CKD-EPI creatinine–cystatin C equation for eGFR reporting? (multiple responses allowed) | |||||
| Limited cystatin C testing options | 1310 (58.5) | 274 (58.5) | 716 (59.6) | 231 (58.2) | 89 (51.7) |
| Cost of testing | 523 (23.4) | 105 (22.4) | 282 (23.5) | 95 (23.9) | 41 (23.8) |
| Staffing resourcese | 519 (23.2) | 119 (25.4) | 297 (24.7) | 67 (16.9) | 36 (20.9) |
| Patient populationf | 257 (11.5) | 48 (10.3) | 124 (10.3) | 53 (13.4) | 32 (18.6) |
| Other | 448 (20.0) | 91 (19.4) | 234 (19.5) | 90 (22.7) | 33 (19.2) |
| Total respondents | 2239 | 468 | 1202 | 397 | 172 |
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate.
P < .001 for comparison of hospital/medical center (academic) vs physician office laboratory/clinic. P = .02 for comparison of hospital/medical center (nonacademic) vs physician office laboratory/clinic. Other comparisons were not significant.
P = .008 for comparison of hospital/medical center (nonacademic) vs nonhospital laboratory. P = .003 for comparison of nonhospital laboratory vs physician office laboratory/clinic. Other comparisons were not significant.
P = .005 for comparison of hospital/medical center (academic) vs physician office laboratory/clinic. P < .001 for comparison of hospital/medical center (nonacademic) vs physician office laboratory/clinic. Other comparisons were not significant.
None of the comparisons was statistically significant.
P = .01 for comparison of hospital/medical center (academic) vs nonhospital laboratory. P = .008 for comparison of hospital/medical center (nonacademic) vs nonhospital laboratory. Other comparisons were not significant.
P = .03 for comparison of hospital/medical center (academic) vs physician office laboratory/clinic. P = .01 for comparison of hospital/medical center (nonacademic) vs physician office laboratory/clinic. Other comparisons were not significant.